The Red Bull crew traveled to Wisconsin for a one-of-a-kind wakeboarding experience on a cranberry bog.
It reportedly included white characters referring to “savages”.
The "North America Cut Flowers Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Flower Type, and Application" report has been added to ResearchAndMarkets.com's offering.
The global wearable payments devices market size is expected to reach USD 80.39 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 29.8% from 2021 to 2028. Over time, payment systems have adapted to suit the needs of customers, such as increased convenience and reduced time while making payments. The growing popularity of contactless payment technology, coupled with the increasing adoption of wearable devices, such as smartwatches for contactless payments, is expected to fuel the market growth over the forecast period.
Glenn Herman a New York City slip and fall accident attorney discusses the dangers of walking on snowy and icy streets and sidewalks and climbing snowy and icy stairs during NYC winters. Glenn Herman Manhattan Slip and Fall Injury Lawyers If you have been injured in a slip and fall accident in the Bronx, Manhattan, Brooklyn or Queens, do not hesitate to find out how to stand up for your rights. CALL: 212-966-1928 | 718-590-5616 Your Recovery is Our #1 Priority! NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- As we face yet another New York winter filled with snowstorms and cold temperatures, it is a good time to consider the safety rules that property and business owners are required to comply with to prevent injuries to pedestrians occurring on the streets, sidewalks, steps and stairways of New York City. There are many reasons why every winter there is an increase in trip slip and fall Injuries in NYC. Glenn Herman an NYC slip and fall lawyer educates New Yorkers on how to understand how injuries occur and how they could be avoided, and what to do if a slip and fall accident happens. Failing to comply with the applicable safety rules that keep people safe can result in those property and business owners being responsible for injuries that happened on and adjacent to their premises. Lawyer Resource on New York City Slip and Fall Accidents >> https://hermannyc.com/nyc-slip-trip-and-fall-attorney/ << Every year freezing weather in NYC leads to a rise in trip, slip and fall injuries. A large number of New Yorkers who were injured by slipping on snowy and icy streets and sidewalks or ascending and descending snow covered and ice covered stairs have been entitled to compensation from their injury claims. In NYC, the laws that govern personal injury cases are quite complex. If you have suffered an injury that was the result of someone else’s negligence, you should consult a New York City slip and fall accident lawyer and personal injury attorney at the law firm of Herman & Herman PC. Our experienced professionals can help you decide if the injury you suffered as a result of a negligent third party trip, slip and fall is worthy and has merit to be filed as a claim and potentially put into a lawsuit. As personal injury lawyers in NYC, we are familiar with the relevant rules and regulations and also with workplace laws, and the different types of insurance required to protect individuals who may become victims of a slip and fall accident. Who is responsible for slip and fall injuries? Wintertime slip, trip and fall accidents often happen when property and business owners fail to remove the snow and ice on the sidewalks and stairs outside their premises. Most injuries occur not because the victim was not paying attention. Rather, the property or business owner who is, or should be aware, that a snow and ice condition exists, chooses not to remedy or remove the hazard. Winter slip and fall cases in NYC fall under a broad category known as ‘premises liability’. Under this area of law, property owners and businesses are responsible to provide a safe environment and if they fail to do so, and someone is injured as a consequence, they may be held liable for medical expenses, pain and suffering, lost wages and in certain cases future economic damages in the severest of cases. As per NYC laws, property and business owners of all kinds are legally obligated to take proper precautions with slippery stairs or walkways, otherwise serious injuries are inevitable! In NYC, the laws that govern snow and ice personal injury cases can be quite complex. The New York City Administrative Code §16-123, entitled “Removal of snow, ice and dirt from sidewalks; property owners duties,” provides in part that: a. Every owner, lessee, tenant, occupant, or other person, having charge of any building or lot of ground in the city, abutting upon any street where the sidewalk is paved, shall, within four hours after the snow ceases to fall, or after the deposit of any dirt or other material upon such sidewalk, remove the snow or ice, dirt, or other material from the sidewalk and gutter, the time between nine post meridian and seven ante meridian not being included in the above period of four hours. Such removal shall be made before the removal of snow or ice from the roadway by the commissioner or subject to the regulations of such commissioner. In the boroughs of Queens and Staten Island, any owner, lessee, tenant or occupant or other person who has charge of any ground abutting upon any paved street or public place, for a linear distance of five hundred feet or more, shall be considered to have complied with this section, if such person shall have begun to remove the snow or ice from the sidewalk and gutter before the expiration of such four hours and shall continue and complete such removal within a reasonable time. b. In case the snow and ice on the sidewalk shall be frozen so hard that it cannot be removed without injury to the pavement, the owner, lessee, tenant, occupant or other person having charge of any building or lot of ground as aforesaid, may, within the time specified in the preceding subdivision, cause the sidewalk abutting on such premises to be strewed with ashes, sand, sawdust, or some similar suitable material, and shall, as soon thereafter as the weather shall permit, thoroughly clean such sidewalks. The above regulation applies to public sidewalks and walkways. If your injury occurs on private property, including parking lots, often different legal standards apply that require snow and ice to be removed or remedied within a reasonable time after a snowfall has ceased. Moreover, if your fall occurs on a public sidewalk or on public (City owned) property, or on property owned or used by public agencies such as The New York City Transit Authority, The MTA, Long Island Rail Road, The Metro North RailRoad, New Jersey Transit or other such property, certain rules apply that require a claim to made a short time after your injury. In most cases, a Notice of Claim must be filed against the responsible parties within 90 days. Accordingly, in such cases, legal advice should be sought immediately. Pedestrians should also be aware that the “storm in progress” rule will often prevent business and property owners from being responsible for injuries that occur while snow or freezing rain is falling. The rationale for this is that a property owner is not able to keep the premises safe while the storm is occurring. Of course, as with most legal rules, there are exceptions that should be explored on a case by case basis. During winter months, even when no snow or ice has fallen, pedestrians can be injured because of hidden hazards because of dangerous conditions that property owners failed to correct. Among the hidden hazards or dangerous conditions that can lead to valid slip and fall claims are; Defective flooring Uneven sidewalks Poor lighting Wet floors Unsafe stairways or steps Hidden drop-offs or holes Improperly secured floor mats Improper or no handrails Unsafe ramps The above list is by no means exhaustive and many people have suffered disabling injuries from all types of unsafe conditions that exist on property, both private and public. What to do if you have had a slip and fall injury. In the United States, typically up to half of all sidewalks remain unclear after a snowfall, and of those hospitalized for pedestrian-related injuries, almost 30% are caused by icy surfaces. These wounds included broken bones, shattered hips, back injuries, and in the most extreme cases fatalities may occur. Usually, minor injuries such as small cuts and bruises are unlikely to merit compensation, however, the injury that causes large amounts of pain to the victim and prevents them from working for a period of time is far more likely to lead to a successful bodily injury claim. The first thing to do is call for help. If you are unable to call for help or do not have a cell phone, ask anyone nearby to call 911. First and foremost, seek the medical attention you need. If you are able to take photos of the condition that caused your fall. Whether it is snow or ice or some other condition. A photo of the condition will assist in often proving that a slip and fall was not your fault. If you are unable to photograph the condition, ask someone else at the scene or have a friend or family member return to the scene as soon as possible to take photographs. Obtain the name and contact information of any witnesses to your fall or people who saw the condition that caused your injury. Even if you’re able to get up by yourself and believe you’re okay, it’s still a good idea to take photos and report the incident to the police as very often injuries develop hours laters. When should you call a trusted personal injury attorney? If you have suffered an injury that was the result of someone else’s negligence, you should consult a New York City slip and fall accident lawyer and personal injury attorney at the law firm of Herman & Herman PC. Our experienced professionals can help you decide if the injury you suffered has merit to be filed as a claim and potentially put into a lawsuit. As personal injury lawyers in NYC, we are familiar with the legal requirements to bring a case on your behalf. Additionally, all calls and consultations are free of charge. A fee is only charged if your case is accepted and a recovery is made on your behalf. With the representation of a New York personal injury attorney, you may be able to receive a significant monetary award as fair compensation and recovery for your trip, slip and fall injuries. Including, but not restricted to pain and suffering, loss of wages if you cannot work and your hospital and medical bills covered that you have incurred and economic damages in career ending cases. We can help you determine if you have a case. The New York personal injury lawyer and attorneys of Herman & Herman have successfully represented slip and fall incident cases in New York. If you have been injured in a slip and fall accident in the Bronx, Manhattan, Brooklyn or Queens, do not hesitate to find out how to stand up for your rights. Our personal injury lawyers also offer a free initial consultation. Book your consultation online today to find more information or to get a free case evaluation. Get in touch with us at 718-590-5616; to find out how we can help you get the maximum injury compensation you’re entitled to! Resources: "Manhattan Women Injured in Her Apartment by Contractors Jury Verdict $1,100,000.An 87 year old woman slipped and fell in her apartment on a plastic drop sheet left by contractors during renovation work. The client sustained a fracture to her hip requiring hip replacement surgery. A Bronx jury awarded the client the above amount for her pain and suffering." "Westchester woman breaks ankle in a parking lot Settlement $350,000. a 45-year-old woman slipped and fell on an algae condition in a shopping center parking fracturing her ankle and requiring two surgeries. We determined that the algae was caused by runoff water from the lawn in front of a Chase bank and retained a safety expert to support this theory. The case settled during jury selection." Source [NYC Slip, Trip And Fall ( Premises Liability) Injuries] We’ll Come To You. We are fully-operational during COVID-19 - Attorney Advertising https://hermannyc.com/attorney-advertising-terms-of-service/ Media contact: R. William 718-590-5616 Sources: https://codelibrary.amlegal.com/codes/newyorkcity/latest/NYCadmin/0-0-0-26213 This news has been published for the above source. Manhattan Injury Lawyer Herman & Herman [ID=16634] Disclaimer: The information does not constitute advice or an offer to buy. Any purchase made from this story is made at your own risk. Consult an expert advisor/health professional before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling. The content publisher and its distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about. Attachments Glenn Herman Manhattan Slip and Fall Injury Lawyers CALL: 212-966-1928 | 718-590-5616
New report from Mobilesquared and Interop Technologies indicates that MNOs stand to gain a 240% revenue uplift over the forecast period by launching a native RCS solution Safeguarding Revenue from A2P Messaging: An in-depth guide to how RCS will help operators remain at the centre of mobile messaging Cover of image of joint white paper LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rich messaging is becoming a key platform connecting brands with consumers, joining the list of mainstream marketing channels alongside TV, the internet, and social media, according to the findings of a new report by business messaging intelligence experts, Mobilesquared. By the end of 2024 there will be more than 3 billion RCS users, representing an unparalleled growth rate of 294%. This high rate of growth is set to position RCS as the largest enhanced messaging platform globally and provide new revenue opportunities for mobile operators. The report, Safeguarding Revenue from A2P Messaging, published by Mobilesquared in partnership with Interop Technologies, highlights how RCS’ growth will help operators remain at the centre of mobile messaging. The only business messaging channel currently generating sizeable revenue anywhere in the world remains A2P SMS. Brands spent $17.9 billion on the channel in 2020, and that will grow to $18.94 billion in 2021. Mobile operators hold a very dominant position when it comes to business messaging for now. However, they need to safeguard future messaging revenues by consolidating legacy messaging and migrating subscribers to an RCS messaging platform to capitalize on its continued growth and next-gen technology synergies. As the official 5G messaging service, RCS is expected to become an essential vehicle for generating future messaging revenues for mobile operators. Consumers are already reliant on rich messaging, brands want it, and mobile operators need to deliver it. Based on existing RCS and MaaP deployment plans from around the world, Mobilesquared forecasts that RCS will generate revenues of $8.3 billion by 2024 from the traditional telco A2P SMS model. Delaying an RCS launch will only risk mobile operators’ ability to generate new messaging revenue and their position in the channel. “Mobile operators need to take a holistic look at their A2P strategy to ensure current revenues generated from SMS aren’t being left on the table,” said Jim Dwyer, Senior Vice President of Corporate Development and Product Management at Interop Technologies. “At the same time, operators must also prepare their messaging networks for the predicted eruption of new revenue opportunities that will be delivered through RCS via conversational commerce interactions between brands and consumers.” Nick Lane, Chief Insight Analyst, Mobilesquared, said: “Over 3 billion people use rich messaging, so if the mobile operators want to ensure their platforms remain relevant to their customers, they must evolve SMS into RCS. SMS has served them well, and in an A2P environment will continue to do so, but the level of engagement on rich messaging takes the opportunity to a different stratospheric level altogether.” Having a robust messaging platform is now seen as a vital component in mobile operator competitiveness, to such an extent that it can improve subscriber quality of experience and also reduce churn. By developing a native RCS offering to subscribers, it ensures that mobile operators remain at the centre of the next major platform, both for consumers and for brands. The report, ‘Safeguarding Revenue from A2P Messaging’, can be downloaded here: https://mobilesquared.co.uk/ About Interop TechnologiesInterop Technologies assists mobile network operators with better ways to deploy and manage next-generation technologies and services. Founded in 2002, the company develops Telco-grade, standardized mobile solutions with the highest level of deployment flexibility and lifecycle management. Interop Technologies’ portfolio includes an industry-leading, accredited, end-to-end RCS Business Messaging Platform with global connectivity for legacy integration to prepare operators for their 5G transformation. Interop Technologies is headquartered in Fort Myers, FL, and has EMEA regional headquarters in Dublin, Ireland. The company owns and operates network operation centers in North America and Europe. Learn more at interoptechnologies.com. About Mobilesquared#1 for business messaging intelligence. Mobilesquared is the go-to partner for definitive business messaging market intelligence. We own the most comprehensive independent global messaging market forecasts in the industry, trusted by brands including Mastercard, Google, Vodafone, LivePerson, and PwC for accuracy and impartiality. If you need targeted messaging market insight and future-proofed strategy, we can help. Learn more at mobilesquared.co.uk. Contact Information Interop TechnologiesLisa Murray, APR, CPRC Sr. Manager, Corporate Communicationslisa.murray@interoptechnologies.com +1 (239) 425 9079 MobilesquaredNick Lane Chief Insight Analystnick@mobilesquared.co.uk +44 (0) 118 2149 777 An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b594f39-2de1-4c00-92cb-98196aa3148c
The cold hits you first. Then comes the smell.
After two Democratic senators voiced support for the longstanding filibuster rule, McConnell signaled a willingness to move forward.
With calls for a cancellation mounting, pressure is building on Japanese organizers and the IOC to explain exactly how they plan to hold the Tokyo Olympics in the midst of a pandemic. The International Olympic Committee and the local organizers are expected to roll out “Playbooks” next week that are to provide step-by-step details about how athletes and thousands of others will get safely in and out of Tokyo. Both the organizers and the IOC have been vague for months, opening the door to speculation about a cancellation, or another postponement.
(Bloomberg) -- The Czech Republic may raise interest rates as many as two times this year, central bank Governor Jiri Rusnok said, departing from the global trend of pursuing ultra-loose monetary policy against the Covid-19 crisis.Rusnok, speaking in an interview, said he sees economic growth picking up in the second half of the year, partly due to progress on vaccinations. He said unemployment, which is the European Union’s lowest, is also expected to remain subdued and keep pressure on consumer prices.Like other nations across Europe, the Czechs have locked down their retail and hospitality industries to get a grip on the pandemic. The export-dependent economy is selling cars, electronics and other goods everywhere from Germany to China to drive economic growth.“We will tread very cautiously to make sure we don’t undercut the fragile economic recovery by acting too early or tightening monetary conditions too fast,” Rusnok said in an interview on Monday. “Other than that, the outlook for gradual rate hikes is still valid and we’ll be mainly fine-tuning the timing.”The koruna gained 0.2% against the euro after Rusnok’s comments as the money market began pricing in a higher likelihood of rate hikes.Czech policy makers differ from their counterparts in the euro area and central Europe, who are extending monetary easing to support growth and maintain low government financing costs.Read more: Czechs Cede Debt Aversion With a Repeat of Record Deficit TargetThe nation of 10.7 million still has more available jobs than people seeking work and an aging population, which has kept price growth above the central bank’s 2% target. The labor shortage is driving up salaries and won’t disappear when the government ends relief programs, according to the governor.“We entered the crisis with a very dynamic economy that even showed some signs of overheating, especially in the labor market and to some extent in real-estate prices,” he said. “So our inflationary potential is incomparably higher than in the euro area.”Still, a stronger koruna and risks to the recovery mean rates probably won’t rise three times this year as implied in the central bank’s November projection, said Rusnok.“The pace of rate normalization could be roughly in line with our forecast, but the whole process will be slightly delayed in time,” he said. “I don’t know if we’ll do zero, one or two hikes.”The Czechs stand out in Europe by rejecting unconventional monetary tools. Relatively low public debt and surplus bank liquidity are helping finance record budget deficits without quantitative easing.While the government’s longer-term debt yields have jumped the most in Europe over the past three months and are higher than in junk-rated Greece, Rusnok doesn’t see a need for the bank to start asset purchases. Yields are still low, with negative real interest rates that are below those in the euro area, he said.Policy makers are debating non-standard tools to have them ready if needed, but they’d only use them to fulfill their goal of safeguarding price and financial stability, according to the governor.“It’s not a taboo for us,” he said. “But it certainly isn’t something that we would be thinking about as a policy move in the foreseeable future.”(Updates with koruna gains in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Dublin, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The "Web Filtering - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Web Filtering Market to Reach $7.3 Billion by 2027Amid the COVID-19 crisis, the global market for Web Filtering estimated at US$3.1 Billion in the year 2020, is projected to reach a revised size of US$7.3 Billion by 2027, growing at a CAGR of 12.7% over the analysis period 2020-2027. DNS Filtering, one of the segments analyzed in the report, is projected to record a 12.5% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the URL Filtering segment is readjusted to a revised 11.8% CAGR for the next 7-year period.The U. S. Market is Estimated at $926.7 Million, While China is Forecast to Grow at 12.3% CAGRThe Web Filtering market in the U. S. is estimated at US$926.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 12.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 10.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.Keyword Filtering Segment to Record 14.7% CAGRIn the global Keyword Filtering segment, USA, Canada, Japan, China and Europe will drive the 14.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$464 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$862.8 Million by the year 2027. We bring years of research experience to this 6th edition of our report. The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & REPORT SCOPEII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Global Competitor Market SharesWeb Filtering Competitor Market Share Scenario Worldwide (in %): 2019 & 2025Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS AO Kaspersky LabBarracuda Networks, Inc.CensorNet Ltd.Cisco Systems, Inc.Clearswift Ltd.ContentKeeper Technologies Pty., Ltd.Cyren Ltd.Forcepoint LLCFortinet, Inc.GFI Software Ltd.Iboss, Inc.International Submarine Engineering (ISE) Ltd.McAfee LLCNetskope, Inc.Palo Alto Networks, Inc.Sophos Ltd.Symantec CorporationTitanHQ c/o Copperfasten TechnologiesTrend Micro, Inc.Trustwave Holdings, Inc.Untangle, Inc.Virtela Technology Services, Inc.Wavecrest Computing, Inc.Webroot, Inc.Zscaler, Inc. 3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE DNS Filtering (Filtering Type) World Market by Region/Country in US$ Million: 2020 to 2027DNS Filtering (Filtering Type) Historic Market Analysis by Region/Country in US$ Million: 2012 to 2019DNS Filtering (Filtering Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027URL Filtering (Filtering Type) Potential Growth Markets Worldwide in US$ Million: 2020 to 2027URL Filtering (Filtering Type) Historic Market Perspective by Region/Country in US$ Million: 2012 to 2019URL Filtering (Filtering Type) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027Keyword Filtering (Filtering Type) Geographic Market Spread Worldwide in US$ Million: 2020 to 2027Keyword Filtering (Filtering Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2012 to 2019Keyword Filtering (Filtering Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027File Type Filtering (Filtering Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2020 to 2027File Type Filtering (Filtering Type) Market Historic Review by Region/Country in US$ Million: 2012 to 2019File Type Filtering (Filtering Type) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027Other Filtering Types (Filtering Type) World Market by Region/Country in US$ Million: 2020 to 2027Other Filtering Types (Filtering Type) Historic Market Analysis by Region/Country in US$ Million: 2012 to 2019Other Filtering Types (Filtering Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027On-Premises (Deployment) World Market Estimates and Forecasts in US$ Million by Region/Country: 2020 to 2027On-Premises (Deployment) Market Worldwide Historic Review by Region/Country in US$ Million: 2012 to 2019On-Premises (Deployment) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027Cloud (Deployment) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2020 to 2027Cloud (Deployment) Global Historic Demand in US$ Million by Region/Country: 2012 to 2019Cloud (Deployment) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 III. MARKET ANALYSISGEOGRAPHIC MARKET ANALYSIS Market Facts & FiguresWeb Filtering Market Share (in %) by Company: 2019 & 2025Market AnalyticsWeb Filtering Market Estimates and Projections in US$ Million by Filtering Type: 2020 to 2027Web Filtering Market by Filtering Type: A Historic Review in US$ Million for 2012-2019Web Filtering Market Share Breakdown by Filtering Type: 2012 VS 2020 VS 2027Web Filtering Market in US$ Million by Deployment:2020-2027Web Filtering Market Retrospective Analysis in US$ Million by Deployment: 2012-2019Web Filtering Market Share Breakdown by Deployment: 2012 VS 2020 VS 2027 IV. COMPETITION Total Companies Profiled: 41 For more information about this report visit https://www.researchandmarkets.com/r/b0yrn6 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The clinical alarm management market statistics covered in this report will be a beneficial guide to form the business growth. Research report highlighted market growth in North America, South America, Asia, Europe and Middle East.Dallas, Texas, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The “Global Clinical Alarm Management Market Size 2020, By Product (Nurse Call Systems, Physiological Monitors, EMR Integration Systems, Bed Alarms, Ventilators, Others) End-Use (Hospitals, Long-Term Care Centers, Ambulatory Care Centers & Home Care Settings) Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) and Forecast 2021 to 2028” study provides an elaborative view of historic, present and forecasted market estimates. The global clinical alarm management market is projected to reach USD 5,780.1 million by 2028, growing at a CAGR of 30.6%. Increasing alarm fatigue, up surging elderly population, and growing importance and practice of big data and mHealth tools are some of the factors driving the growth of the global clinical alarm management market. Request for Sample Report: https://www.adroitmarketresearch.com/contacts/request-sample/1846 The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global clinical alarm management market have been studied in detail. The global clinical alarm management market is categorized based on product and end-use. On the basis of product, the market is segmented into nurse call systems, physiological monitors, EMR integration systems, bed alarms, ventilators, and others. The nurse call systems dominated the market in 2020. By end-use, the market is segmented into hospitals, long-term care centers, and ambulatory care centers & home care settings. The ambulatory care centers & home care settings segment is anticipated to record the highest CAGR through the forecast period. Read the complete report: https://www.adroitmarketresearch.com/industry-reports/clinical-alarm-management-market North America dominated the market for clinical alarm management in 2020, while Asia-Pacific is set to grow at the highest CAGR in order to advance access to information. Key players of the global clinical alarm management market include Koninklijke Philips, Ascom Holdings, Vocera Communications, Spok, Inc., Connexall, Bernoulli Enterprise, Mobile Heartbeat, Capsule Technologie, GE Healthcare Masimo Corporation among others. Key segments of the global clinical alarm management market Product Overview, 2018-2028 (USD Million) Nurse call systemsPhysiological monitorsEMR integration systemsBed alarmsVentilatorsOthers End-use Overview, 2018-2028 (USD Million) HospitalsLong-term care centersAmbulatory care centers & home care settings Regional Overview, 2018-2028 (USD Million) North AmericaU.S.CanadaEuropeGermanyUnited KingdomFranceAsia PacificRest of the world Interested to Procure The Data? Inquire here at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1846 Table of Contents: 1. Introduction 2. Research Methodology 3. Market Outlook 4. Clinical alarm management Market by Product, 2018-2028 (USD Million) 5. Clinical alarm management Market by End-use, 2018-2028 (USD Million) 6. Clinical alarm management Market by Region 2018-2028 (USD Million) 7. Competitive Landscape 8. Company Profiles Have a Look at Related Reports: Global Nurse Call Systems Market Size 2018, By Type (Integrated Communications Systems, Mobile Systems, Button-based Systems, Intercom Systems), Technology (Wired Nurse Call Systems, Wireless Nurse Call Systems), Application (Workflow Optimization, Fall Detection & Prevention, Alarms & Communication, Wanderer Control), End-users (Hospitals, Ambulatory Surgical Centers (ASCs) & Clinics, Long-term Care Facilities), Region and Forecast 2019 to 2025 Global Remote Patient Monitoring Market Size 2019, By Product [Vital Signs (Heart Rate, Blood Pressure, Pulse Oximeters, Respiratory Rate, EEG, Temperature) and Special Monitors (Blood Glucose, Anesthesia, Cardiac Rhythm, Respiratory, Prothrombin, Multiparameter, Fetal Heart Rate)], By Application, By Usage Area, By Region and Forecast 2020 to 2026 Global Resuscitation Devices Market Size 2018, By Product (Airway Management Devices {Endotracheal Tubes, Ventilators, Laryngeal Masks, Resuscitators, Others}, External Defibrillators {Semi-automated External Defibrillators, Automated External Defibrillators, Wearable Cardioverter Defibrillators}, others), Patient group (Adults, Pediatric), End-users (Hospitals & Cardiac Centers, Pre-hospital Care Settings, Others), Region and Forecast 2019 to 2025 Access research repository of Upcoming Reports @ https://adroitmarketresearch.com/upcoming.html About Us: Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps. Contact Us: Ryan Johnson Account Manager - Global 3131 McKinney Ave Ste 600 Dallas, TX 75204 Email ID: sales@adroitmarketresearch.com Phone No.: +1 972-362 -8199 Connect with us: Facebook | Twitter | LinkedIn
People aged 25 to 34 face the highest risk of redundancy as Covid pushes up the jobless rate to 5%.
Perez was a former elected official in suburban Montgomery County before joining the Obama Administration as labor secretary.
GettyOur wardrobe staples are changing. The continued lockdown has meant that where we used to have work wardrobes, going-out clothes, and casual wear, we’ve now been reduced to that same ratty T-shirt and leggings most days.Yet shapewear—typically worn at special occasions, formal gatherings, dates, and other things that are non-existent right now—is holding on.Despite women spending literally dozens of Friday nights on the couch over the past year, Spanx is making it through the pandemic better than many clothing brands. Online searches for shapewear are faltering slightly, but in comparison to the dozens of clothing retailers that have declared bankruptcy since the start of the pandemic—like J. Crew, Neiman Marcus and Century 21—shapewear has adapted to our suddenly home-based working and relaxing lives.It’s the Great War of Kim Kardashian’s Skims Versus Spanx—but What Shapewear Do Women Really Want?“We'll be taking the notion of comfort in clothing with us post-COVID, even when we're back out and about—going to work and socializing again—and shapewear is going to have to appreciate that new mindset,” said Elizabeth Shobert, VP of Marketing and Digital Strategy at StyleSage.“I also think the body-positivity movement will continue its momentum and that shapewear brands will want to be careful to use language that doesn't go against that grain.”After promoting leggings marketed as perfect for those staying home for the holidays last month, Spanx is pushing athletic wear on its Instagram page at the start of the year. Kim Kardashian West opened a new line of shapewear not long before the pandemic began and started selling maternity styles and loungewear in 2020.Despite there being nowhere to go—or nowhere you’re supposed to go—since last March, some people have still found reason to bring out their shapewear. Whether it’s nostalgia for the days of dressing up and going out, brand loyalty or wanting to try out the new products that the industry has been developing, people are still interested.this was the only passable photo this is us exiting 2020 (I wore spanx to the zoom party) pic.twitter.com/IQEYHdjHuB— brennuary bones (@BonniePuns) January 1, 2021 Meanwhile, we're "ringing" in the New Year the best we know how: a onesie and SPANX! @jessicavosk pic.twitter.com/KuB5NavhEd— SPANX (@SPANX) December 30, 2020 Mommy & daughter cozy in our @skims 🤞🏼🤍 pic.twitter.com/PcXsmm4dwk— miri (@miriacvd) January 1, 2021 During pre-pandemic times, New York actress Jessica Vosk wore shapewear regularly for performances, tapings and almost anything work-related.But even in the pandemic, and in fact especially during the pandemic, she’s found herself bringing them out. “Shapewear to me had always been like that little security blanket you carried around as a kid. Makes you feel better, makes you feel secure. At least, it’s always been that way for me,” Vosk told The Daily Beast.Leggings are now prominently displayed on the Spanx website, with a phrase that has basically become synonymous with pandemic style when we’re wearing the same pants day in and day out: “comfiest, everyday go-to.”For Vosk leggings are a key part of shapewear’s appeal currently. She recently bought a pair of black Spanx brand leggings that she is “absolutely obsessed” with.“Will I buy more [leggings]? The limit does not exist,” Vosk said.Los Angeles resident Brenna White has busted out her Spanx occasionally during the pandemic, even if it’s just to dress up for a take-out meal. “Even though I’m not going out, it is nice to pull on shapewear like Spanx (that I invested in) to see the curves of my body and put on outfits I used to wear,” the 34-year-old said. She hates thinking of her nicest outfits “wasting away” in the closet, and shapewear is inseparable from that.Despite these personal stories of devotion, the pandemic has affected the shapewear industry. Online searches for shapewear are down 28% year-over-year and new shapewear styles are down 30%. “That would have to suggest to me that if that's not an outright rejection of shapewear, at the very least there's been a significant decrease in interest in shopping and wearing it [since the start of the pandemic],” said Shobert.“With what we know about the popularity of sweatpants and leggings throughout the pandemic, it's kind of hard to envision adding shapewear to that comfortable mix,” she said.Yet the industry’s gradual pivot away from restrictive high-rise and high-compression underclothes and towards comfort and support gives shapewear—pun intended—room to grow. Kardashian’s maternity clothes garnered enthusiasm and criticism when they were launched. Kardashian’s SKIMS shapewear line expanded sales to both the United Kingdom and the Middle East months into the pandemic.New to the Spanx world is the Spanx Men’s line added in the first week of 2021, which includes underwear and undershirts with varying degrees of compression.Spanx CEO Sara Blakely, who’s now worth over $600 million according to Forbes, said she’s taking the current crisis and trying to view it as an opportunity. “The narrative for all of your customers has changed, so your narrative has to change,” Blakely told LinkedIn during a podcast interview this spring. She said the company is coming up with ideas for new items, which she declined to share, and thinking about how to create a “new normal” for shoppers who are stuck at home.“I personally will always be Team Spanx hehe,” my friend from grad school texted me when I told her I was writing this story. Shapewear is by nature a personal thing. A relationship like that—between human and articles of clothing so intimately and personally worn—can’t be easily broken. We dream of the post-pandemic time when it returns to help us feel fabulous on a night out. And until then, it can stay the trusted friend that helps us relax at home.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
"I think there's a different world where I stayed and kind of tried."
The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
In places where periodical cicadas emerge en masse, "the noise is just head-splitting."
Republicans say Biden's aggressive agenda doesn't reflect his unity talk. Biden says unity is more than just bipartisanship in Congress.
It's not just shoppers facing surprise costs when EU parcels arrive, but what is behind the charges?
Kobi Wolf/Bloomberg via GettyBy Liz Szabo, Sarah Jane Tribble, Arthur Allen, and Jay HancockAmericans are dying of COVID-19 by the thousands, but efforts to ramp up production of potentially lifesaving vaccines are hitting a brick wall.Vaccine makers Moderna and Pfizer-BioNTech are running their factories full tilt and are under enormous pressure to expand production or collaborate with other drug companies to set up additional assembly lines. That pressure is only growing as new viral variants of the virus threaten to launch the country into a deadlier phase of the pandemic.President Joe Biden has said he plans to invoke the Cold War-era authority of the Defense Production Act to provide more vaccines to millions of Americans. Consumer advocates—who had called for Donald Trump to use the Defense Production Act more aggressively as president—are now asking Biden to do the same.But even forcing companies to gear up production won’t provide much-needed doses anytime soon. Expanding production lines takes time. Establishing lines in repurposed facilities can take months.“The big problem is that even if you can get the raw material and get the infrastructure set up, how do you get a company that is already producing at maximum capacity to go beyond that maximum capacity?” said Lawrence Gostin, a professor of global health law at Georgetown University.Ordering the companies to work 24/7 “would be a naïve solution,” said Dr. Nicole Lurie, a senior adviser to the CEO of the Coalition for Epidemic Preparedness Innovations, an international group that finances vaccines for emerging diseases. “They’re probably already doing that to the extent they have the raw materials.”The Medical Miracles COVID Vaccines Make PossibleLurie added, “If you completely wear people out, mistakes happen. You have to balance speed with quality and safety.”The technological challenges involved are daunting, and the companies haven’t been forthcoming about what’s needed to overcome any supply shortfalls.“We don’t know what the holdup is. Is it capacity? Raw materials? People? Glass vials? We just don’t know what the bottleneck is,” said Erin Fox, senior director of drug information and support services at the University of Utah Health Hospitals.Forcing other companies to start making the vaccines might not work either, Gostin said.“I’m not sure if Biden could require a private company to transfer its technology to another company,” Gostin said. “That is highly questionable legally… President Biden’s room for maneuvering isn’t as great as people think.”Drug companies define “trade secrets” broadly, Fox said. “In general, drug companies don’t have to tell me who is making their product, where it’s made, the location of the factory… That’s considered proprietary.”Part of the challenge relates to how these vaccines are made. The first two authorized products use lipid nanoparticles to deliver a snippet of the coronavirus’ genetic material—called messenger RNA, or mRNA—into cells. The viral genes teach our cells how to make proteins that stimulate an immune response to the novel coronavirus.Messenger RNA is fragile and breaks down easily, so it needs to be handled with care, with specific temperatures and humidity levels.The vaccines “are not widgets,” said Lurie, who served as assistant secretary for preparedness and response at the Department of Health and Human Services during the Obama administration.Every step, experts say, to get vaccines to market has its complexities: obtaining raw materials; building facilities to precise specifications; buying single-use products, such as tubing and plastic bags to line stainless steel bioreactors; and hiring employees with the requisite training and expertise. Companies also must pass safety and quality inspections and arrange for transportation.The Defense Production Act, for instance, would allow the government to commandeer a plant that already has a fermenter—there are plenty in the biotech industry—to expand production. But that’s just the first stage in making an mRNA vaccine and, even then, it would take about a year to get going, said Dr. George Siber, a vaccine expert who is on the advisory board of CureVac, a German mRNA vaccine company.Companies would first have to do a breathtakingly thorough cleaning to prevent cross-contamination, Siber said. Next they would need to set up, calibrate, and test equipment, and train scientists and engineers to run it. Finally, Siber said, unlike a drug, whose components can be tested for purity, there’s no way to be sure a vaccine produced in a new facility is what it claims to be without testing it on animals and people.“Making vaccines is not like making cars, and quality control is paramount,” said Dr. Stanley Plotkin, a vaccine industry consultant credited with inventing the rubella vaccine. “We are expecting other vaccines in a matter of weeks, so it might be faster to bring them into use.”However, even that will require patience. Johnson & Johnson, expected to announce clinical trial results this month, has said that it won’t be able to deliver as many shots as planned because of manufacturing delays. The company did not confirm a manufacturing delay and declined to respond to questions.AstraZeneca’s vaccine, also funded in part by U.S. taxpayers, is in use already in the United Kingdom and India, but the Food and Drug Administration has raised questions about its late-stage trial, so it may not be available here until the spring.Novavax, another U.S.-funded vaccine maker, has been plagued by delays and only recently began recruiting volunteers for its big trial. Merck, the most recent company to get federal support for COVID vaccines, announced Monday it was scrapping its two candidates after they failed to produce adequate immune response in early tests.“None of the vaccine makers are manufacturing at the volume they ultimately want to be at,” Lurie said. “They all have manufacturing delays.”Pfizer, which has committed 200 million doses to the U.S. government by the end of July, said last week it expected “no interruptions” in shipments from its primary U.S. COVID manufacturing plant in Kalamazoo, Michigan. Pfizer spokesperson Sharon Castillo said the company has expanded manufacturing facilities and added more suppliers and contract manufacturers. Those efforts, and the company’s announcement that its five-dose vials actually contain an extra dose, mean “we can potentially deliver approximately 2 billion doses worldwide by the end of 2021.”The U.S. government also has an option to acquire another 400 million doses of the Pfizer-BioNTech vaccine, though the company declined to provide details on that option when asked.But countries around the world are competing for the same supplies and raw materials, Gostin said.Biden could use the Defense Production Act “to force Pfizer to prioritize U.S. contracts, but that would be politically risky,” given that other countries could retaliate by hoarding supplies. Although Pfizer is an American company, it has partnered with BioNTech, of Germany, to make its COVID vaccine. “That would lead to a global mess.”Trying to corner the world market on vaccine ingredients or supplies would look bad, experts say, given that the United States just this week joined Covax, an international venture to source and distribute vaccines, in an effort to ensure poor countries aren’t left behind.Paradoxically, the rush to get vaccines to market may have resulted in a less efficient manufacturing process.Vaccine companies typically spend months making their factories run as efficiently as possible, as well as finding an ideal dose and the most effective interval between doses, Lurie said. Given the urgency of the pandemic, however, they delayed parts of this process and launched straight into mass production.Pfizer angered European countries last week when it paused vaccine production at a Belgian plant to upgrade its capacity. Pfizer said the weeklong closure would decrease vaccine deliveries to Europe for three to four weeks before boosting supplies in February. The move doesn’t affect U.S. vaccine supplies.“The U.S can’t necessarily readily access stuff that’s being held for vaccines in other countries,” Lurie said.And forcing other companies to make COVID vaccines could jeopardize production of other important shots, such as measles, said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. Routine childhood immunization rates have fallen during the pandemic, raising the risk of epidemics.Using the act to prioritize COVID vaccine manufacturing has already disrupted supplies of at least one drug, Fox noted. In December, Horizon Therapeutics warned doctors and patients to expect a shortage of a drug called Tepezza, used to treat thyroid-related eye disease, because its manufacturer was ordered to prioritize COVID shots.Lawmakers and consumer advocates such as Public Citizen called on the government to use the Defense Production Act more aggressively. In a letter sent earlier this month, Sen. Elizabeth Warren (D-MA) and Rep. Katie Porter (D-CA) said Moderna should share its technique for stabilizing its vaccine at normal refrigerator temperatures, without “ultracold” freezers.Moderna officials have said the intrinsic differences in the two companies’ mRNA material make that technology hard to share. Besides, they say, Pfizer has declined to share data with Moderna. Pfizer has declined to comment on the issue.Since Moderna’s effort is federally funded, the government presumably has march-in rights and could take over production, said Mike Watson, former president of Moderna subsidiary Valera, in an email. “The reality is that however far you push production capacity, you sooner or later reach a bottleneck.”Experts say it’s not as simple as demanding that glassmaker Corning step up and make glass vials, for example. Of course, the vials will need to meet rigorous requirements. But there’s also this: The U.S. is facing a shortage of mined sand, the main component needed to make glass vials.KHN (Kaiser Health News) is a nonprofit news service covering health issues. It is an editorially independent program of KFF (Kaiser Family Foundation) that is not affiliated with Kaiser Permanente.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
Yahoo Home